| 1442104-50-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• CAS: 1442104-50-8
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: PGBBWDFDFWXPQM-BENRWUELSA-N

反应信息

• 作为产物：
  描述：

  2-丁炔 、 邻甲苯胺 在 Ti(pyridine-2,6-bis(4,6-di-tert-butylphenolate))(Bn)₂ 作用下， 以 氘代苯 为溶剂， 反应 1.0h， 生成 、
  参考文献：
  名称：

  双（酚盐）吡啶钛配合物的炔烃加氢胺化和三聚：低价钛中间体的证据和钛（II）的乙烯加合物的合成

  摘要：

  已经合成了一类（ONO）TiX 2（ONO =吡啶-2,6-双（4,6-二叔丁基苯酚酸酯）； X = Bn，NMe 2）钛预催化剂，并进行了晶体学表征。（ONO）TiX 2（X = Bn，NMe 2，X 2 = NPh）配合物是高活性的预催化剂，用于内部炔烃与伯芳基胺和某些烷基胺的加氢胺化。一类钛亚氨基/配体加合物（ONO）Ti（L）（NR）（L = HNMe 2，py; R = Ph，t Bu）也已合成并表征，并据称为中间体提供了结构类似物催化循环。此外，这些配合物表现出不同寻常的氧化还原行为。（ONO）钛2（1）可能通过1的原位生成的具有催化活性的Ti II物种促进富电子炔烃的环三聚。根据反应条件，建议这些Ti II物质是通过Ti亚苄基或亚氨基中间体生成的。甲正式的Ti II复合物，（ONO）的Ti II（η 2 -C 2 H ^ 4）（HNME 2）（7），已经制备和结构表征。

  DOI：

  10.1021/om400080g

文献信息

• [EN] KRAS G12D INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12D
  申请人：JINGRUI BIOPHARMA CO LTD

  公开号：WO2022262686A1

  公开（公告）日：2022-12-22

  Disclosed are novel compounds which are KRAS G12D inhibitors, their synthesis and their use for treating diseases or conditions, such as cancer, and in particular for inhibiting the activity of KRAS G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及新的化合物，它们是KRAS G12D抑制剂，其合成以及用于治疗疾病或病况的方法，例如癌症，特别是用于抑制KRAS G12D的活性，药物组合物包括这些化合物和使用方法。
• Probe compound for detecting and isolating enzymes and means and methods using the same
  申请人：Helmholtz-Zentrum für Infektionsforschung GmbH

  公开号：EP2230312A1

  公开（公告）日：2010-09-22

  The present invention relates to a probe compound that can comprise any substrate or metabolite of an enzymatic reaction in addition to an indicator component, such as, for example, a fluorescence dye, or the like. Moreover, the present invention relates to means for detecting enzymes in form of an array, which comprises any number of probe compounds of the invention which each comprise a different metabolite of interconnected metabolites representing the central pathways in all forms of life. Moreover, the present invention relates to a method for detecting enzymes involving the application of cell extracts or the like to the array of the invention which leads to reproducible enzymatic reactions with the substrates. These specific enzymatic reactions trigger the indicator (e.g. a fluorescence signal) and bind the enzymes to the respective cognate substrates. Moreover, the invention relates to means for isolating enzymes in form of nanoparticles coated with the probe compound of the invention. The immobilisation of the cognate substrates or metabolites on the surface of nanoparticles by means of the probe compounds allows capturing and isolating the respective enzyme, e.g. for subsequent sequencing.

  本发明涉及一种探针化合物，它可以包括酶反应的任何底物或代谢物，此外还包括指示成分，例如荧光染料或类似物。此外，本发明还涉及以阵列形式检测酶的方法，该阵列由任意数量的本发明探针化合物组成，每种探针化合物由代表所有生命形式中中心途径的相互关联的代谢物中的不同代谢物组成。此外，本发明还涉及一种检测酶的方法，该方法涉及将细胞提取物或类似物应用于本发明的阵列，从而导致与底物发生可重复的酶反应。这些特定的酶反应会触发指示剂（如荧光信号），并将酶与各自的同源底物结合。此外，本发明还涉及以涂覆有本发明探针化合物的纳米颗粒形式分离酶的方法。通过探针化合物将同源底物或代谢物固定在纳米颗粒表面，可以捕获和分离相应的酶，例如用于后续测序。
• 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
  申请人：Wuxi Shuangliang Biotechnology Co., Ltd.

  公开号：EP3345906A1

  公开（公告）日：2018-07-11

  The present disclosure relates to 2-arylamino pyridine, pyrimidine, or triazine derivatives, and the preparation method and use thereof. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may act on certain mutated forms of epidermal growth factor receptor, for example the L858R activating mutant, the delE746_A750 mutant, the Exonl9 deletion activating mutant, and the T790M resistance mutant, so as to be used for treatment and prevention of diseases and medical conditions. The 2-arylamino pyridine, pyrimidine, or triazine derivatives may be used for treatment and prevention of cancer. The present disclosure also relates to a pharmaceutical composition comprising 2-arylamino pyridine, pyrimidine, or triazine derivatives, intermediates useful in the manufacture of 2-arylamino pyridine, pyrimidine, or triazine derivatives, and to methods of treatment of diseases mediated by various different forms of EGFR using 2-arylamino pyridine, pyrimidine, or triazine derivatives.

  本公开涉及 2-芳基氨基吡啶、嘧啶或三嗪衍生物及其制备方法和用途。2-芳基氨基吡啶、嘧啶或三嗪衍生物可作用于表皮生长因子受体的某些突变形式，例如 L858R 激活突变体、delE746_A750 突变体、Exonl9 缺失激活突变体和 T790M 抗性突变体，从而可用于治疗和预防疾病和病症。2-芳基氨基吡啶、嘧啶或三嗪衍生物可用于治疗和预防癌症。本公开还涉及包含 2-芳基氨基吡啶、嘧啶或三嗪衍生物的药物组合物，用于制造 2-芳基氨基吡啶、嘧啶或三嗪衍生物的中间体，以及使用 2-芳基氨基吡啶、嘧啶或三嗪衍生物治疗由各种不同形式的表皮生长因子受体介导的疾病的方法。